Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
The SARS-CoV-2 variants of concern (VOC) widespread and breakthrough infections prompted additional preventive measures in fully-vaccinated immunocompromised recipients, including actively treated cancer patients1. Regulatory agencies recommended a third homologous (booster) dose of an mRNA-based vaccine for this condition based on evidence from immunosuppressed organ transplant recipients2. This study aimed to evaluate the safety, immunogenicity, and clinical outcome of two or three doses of BNT162b2 vaccine (tozinameran) in patients with solid malignancies receiving systemic therapies.
Annals of Oncology , article en libre accès, 2022